ViaCyte’s Senior Scientist Anindita Bhoumik analyzes cells in the company’s lab. The pioneering work in stem cell-derived therapy for Type 1 diabetes treatments has been a nearly 20 year journey for the company. The work has given the company a formidable IP portfolio.

ViaCyte’s Senior Scientist Anindita Bhoumik analyzes cells in the company’s lab. The pioneering work in stem cell-derived therapy for Type 1 diabetes treatments has been a nearly 20 year journey for the company. The work has given the company a formidable IP portfolio. Photo by Jamie Scott Lytle.

VIACYTE INC.

CEO: Paul Laikind

Latest Funding Round: $80 million Series D

No. of employees: 60

Investors: Bain Capital Life Sciences, TPG Capital, RA Capital Management and others

Headquarters: Torrey Pines Mesa

Year founded: 1999

Company description: ViaCyte is a pioneer in stem cell-derived therapy for diabetes.

photo

ViaCyte CEO Paul Laikind stands outside the company’s headquarters. Recently, ViaCyte locked down an $80 million funding round for work on a diabetes cure.

In 1998, researchers derived stem cells from human embryos for the first time...

Take 1 minute to subscribe and you'll get this story immediately, plus:

Already a subscriber? Sign in

  • 52 weekly issues
  • Subscriber-only digital content every business day, plus full access to SDBJ.com archives
  • Book of Lists — the most comprehensive business resource in San Diego
  • San Diego 500 — influential business leaders you need to know
Yours for only $129